Actively Recruiting
Phase Ib and IIa Study of 212PbPb-ADVC001 for Safety and Effectiveness in Treating Metastatic Prostate Cancer
Led by AdvanCell Pty Limited · Updated on 2026-02-20
100
Participants Needed
3
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and efficacy of escalating doses of PbPb-ADVC001 in men with metastatic prostate cancer, including those with castration-resistant and hormone-sensitive types. This Phase IbIIa study aims to identify the recommended doses for further study and assess treatment effects in different patient groups based on prior therapies and disease characteristics. In the Phase 1b part, participants receive intravenous PbPb-ADVC001 at increasing doses ranging from 60 to 200 MBq, administered every 6, 4, 2, or 1 weeks over 4 to 6 cycles to find safe and tolerable dose levels. In Phase 2a, participants are randomized to receive either 160 or 200 MBq doses with up to 12 doses given adaptively, allowing treatment pauses and restarts. All participants continue androgen deprivation therapy ADT, with some also receiving androgen receptor pathway inhibitors ARPi depending on their group. Participants undergo regular monitoring for prostate-specific antigen PSA response, imaging assessments for tumor response, and survival outcomes for up to 60 months. Safety and tolerability are closely followed alongside dosimetry measurements. The study includes detailed eligibility screening, ongoing assessments, and a long-term follow-up period to evaluate disease control, progression, and overall survival in men with PSMA-positive metastatic prostate cancer.
CONDITIONS
Brief Title
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Research Team
A
Anna Karmann
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here